pocketful logo light
pocketful logo light
ERIS Lifesciences Ltd logo

ERIS Lifesciences Ltd

NSE: ERIS BSE: 540596

₹1465.80

(0.71%)

Mon, 27 Jul 2026, 02:03 pm

mtf coin illustrationMTF 5x

ERIS Lifesciences Share Price Live Chart

1 Day

(0.71%)

No Result Found

Summary

  • Market Cap (in Cr)

    19373.78

  • Net Profit (in Cr)

    374.67

  • P/B

    6.76

  • Sector P/E

    33.76

  • P/E

    54.84

  • EV/EBITDA

    20.81

  • Debt/Equity (Industry)

    0.26

  • Interest Cover (Industry)

    10.81

  • ROCE (Industry)

    16.40

  • RONW (Industry)

    14.39

  • ROE

    13.77

  • ROCE

    13.29

  • Debt/Equity

    0.97

  • EPS (TTM)

    45.65

  • Dividend Yield

    0.52

  • Book Value

    281.64

  • Interest Cover

    3.11

Analysis

No Result Found

Read More

Financials

Read More

Ratios

Read More

Shareholding

ShareholdersMAR 2026DEC 2025SEPT 2025JUN 2025MAR 2025
Promoters53.9254.8554.8554.8454.85
FII6.396.857.218.408.43
DII20.3520.3219.3618.1718.07
Public19.3317.9918.5718.5918.66
Government00000

Read More

Technical Analysis

RSI

44.17

MACD

1.53

50 DMA

1410.55

200 DMA

1453.13

Support and Resistance

TypeR3R2R1PPS1S2S3
Classic1720.501570.101501.801419.701351.401269.301118.90
Fibonacci1570.101512.651477.151419.701362.251326.751269.30
Camarilla1474.861461.071447.291419.701419.711405.931392.14

Pivots Level: Classic

R3

+300.80

1720.50

R2

+150.40

1570.10

R1

+82.10

1501.80

1419.70
1419.70
Pivot Point
LTP: 1403.50

S1

-68.30

1351.40

S2

-150.40

1269.30

S3

-300.80

1118.90

Moving Average

SMAEMA

Period

Value

  • 10-EMA

    1429.65

  • 20-EMA

    1432.68

  • 30-EMA

    1427.91

  • 50-EMA

    1417.34

  • 100-EMA

    1414.93

  • 200-EMA

    1437.49

Read More

Corporate Actions

Announcement DatePurposeActionEx Date
20 May 2026dividend₹7.21 Dividend /Share29 May 2026
20 May 2026board-meetingsAccounts, Quarterly Results, Interim Dividend
13 Feb 2026board-meetingsQuarterly Results
30 Jun 2025agm
07 Feb 2025dividend₹7.35 Dividend /Share13 Feb 2025
13 Jan 2025dividendInterim Dividend - Rs. - 7.3513 Feb 2025
04 Sept 2024agm
17 Aug 2024agmAnnual General Meeting18 Sept 2024
15 Aug 2023agmAnnual General Meeting18 Sept 2023
07 Aug 2023agm

Read More

Peer Comparison

ERIS Lifesciences Ltd logo

ERIS Lifesciences Ltd

Torrent Pharmaceuticals Ltd logo

Torrent Pharmaceuticals Ltd

Dr Reddys Laboratories Ltd logo

Dr Reddys Laboratories Ltd

Sun Pharmaceutical Industries Ltd logo

Sun Pharmaceutical Industries Ltd

Divis Laboratories Ltd logo

Divis Laboratories Ltd

Cipla Ltd logo

Cipla Ltd

Read More

ERIS Lifesciences Ltd About

ERIS Lifesciences manufactures, markets, and sells generic drugs. The Company provides a wide range of products in chronic and acute therapy segments which includes capsules, tablets, and sachets. Eris Lifesciences also focuses on hypertension, anti-diabetes, metabolic disorders, lipid lowering, and therapeutic areas. Eris Lifesciences serves the pharmaceutical markets in India.

Industry

Pharmaceuticals - Indian - Formulations

Founded

2007

Headquarters

CEO

Amit Indubhushan Bakshi

Employees

Contact

Website icon

Website

http://www.eris.co.in

Email icon

Email

complianceofficer@erislifesciences.com

Phone icon

Phone

91-79-30451000

Location icon

Location

8th Floor Commerce House -IV, Prahladnagar 100 FT Road, Ahmedabad, Gujarat, 380015

Read More

ERIS Lifesciences Ltd Company History

YearHistory
2016
  • The Company acquired 40 registered and unregistered trademarks from Amay Pharmaceuticals Private Limited.
  • The Company acquired 100.00% of the outstanding equity shares of Aprica Healthcare Private Limited.
  • The Company acquired 75.48% of the outstanding equity shares of Kinedex Healthcare Private Limited.
2017
  • The Company was converted to a public limited company and its name was changed to Eris Lifesciences Limited.
  • The Company acquired the trademarks UNION, REUNION, and BON UNION.
  • A fresh certificate of incorporation was issued by the Registrar of Companies, Gujarat, Dadra and Nagar Haveli on February 2, 2017.
2022
  • Eris entered the dermatology therapy segment through the acquisition of Oaknet Healthcare for INR 6,500 million.
2023
  • Eris acquired the Nephrology and Dermatology Branded Formulations business units of Biocon Biologics in India.
2024
  • The Company acquired a 30% stake in Levim Lifetech Private Limited.
  • The Company acquired a 100% stake in Eris Pharmaceuticals Private Limited.

Read More

Deals

Client NameDeal TypeOrder SideQTYAvg PriceDate
MOTILAL OSWAL FINANCIAL SERVICES LIMITEDbulkBuy20790001350.1803 Oct 2024
RAKESH SHAHbulkSell2000000135003 Oct 2024
EMERALD INVESTMENTS LIMITEDbulkSell9886882120122 Aug 2024
EMERALD INVESTMENTS LIMITEDblockSell9886882120122 Aug 2024
INFINITY PARTNERSbulkBuy9886882120122 Aug 2024
INFINITY PARTNERSblockBuy9886882120122 Aug 2024
FRANKLIN TEMPLETON MUTUAL FUNDbulkBuy10942011000.0415 Jul 2024
RAKESH SHAHbulkSell20000001000.1215 Jul 2024
BHIKHALAL CHIMANLAL SHAHbulkSell1280000913.0931 Jan 2024
BHIKHALAL CHIMANLAL SHAHbulkSell820000912.531 Jan 2024

Read More

ERIS Lifesciences Ltd News

Eris Lifesciences to host Q1 FY27 earnings call

Eris Lifesciences will hold an analyst call on July 29, 2026, to discuss Q1 FY27 results. The meeting follows the Board's review of unaudited financials.

23 Jul 2026

companies

Eris Lifesciences Sets FY27 Revenue & Growth Targets

Eris Lifesciences targets 18-20% revenue growth in FY27 with steady EBITDA margins and growth at 1.3 times CVM, supported by Sundae Pens in-sourcing from Q2 FY27.

23 Jun 2026

companies

Eris Lifesciences Q1FY26 presentation details

Eris Lifesciences released its Q1FY26 corporate presentation, highlighting a MAT Mar'26 revenue of ₹3,318 Cr. The company reported strong growth in the anti-diabetes segment.

23 Jun 2026

companies

Eris Lifesciences pays ₹109.12 crore interest on NCDs

Eris Lifesciences Limited completed routine interest payments totaling ₹109.12 crore on two Non-Convertible Debentures tranches on June 8, 2026.

08 Jun 2026

debt-markets

Eris Lifesciences fined by exchanges

Eris Lifesciences was fined ₹4,24,800 each by BSE and NSE for non-compliance with board composition norms. The vacancy has been filled since March 14, 2026.

28 May 2026

companies

Read More

Open Your Free Demat Account

Enter your phone number